DCM
RPTX

Dupont Capital Management’s Repare Therapeutics RPTX Stock Holding History

Dupont Capital Management’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,271
Closed -$181K – 1129
2022
Q4 		$181K Buy
+12,271
New +$184K 0.01% 812

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dupont Capital Management's RPTX Position: Q1 2023 in Review

Dupont Capital Management sold out of Repare Therapeutics (RPTX) in Q1 2023, closing a stake of 12,271 shares — an estimated $181K sold.

Dupont Capital Management first reported a position in RPTX in Q4 2022 and held it in 1 quarter. The position peaked at $181K in Q4 2022. 77 funds tracked by Wall St. Rank hold RPTX as of Q1 2023.

  • Dupont Capital Management reported no remaining Repare Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Dupont Capital Management sold 12,271 Repare Therapeutics shares in Q1 2023, an estimated $181K.
  • Dupont Capital Management first reported a position in Repare Therapeutics in Q4 2022 and held it in 1 quarter.
  • Dupont Capital Management's Repare Therapeutics position peaked at $181K in Q4 2022.
  • 77 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2023.

Based on Dupont Capital Management's 13F filing for Q1 2023, filed 28 Apr 2023.